NSCLC

Krazati + Keytruda Slows Down KRASG12C-Mutated NSCLC (ESMO 2023)

Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-Naïve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)

Anika Sharma

ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...

Keytruda + Chemo Boosts Survival in Resectable NSCLC (ESMO 2023)

KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)

Anika Sharma

ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merck’s Keytruda is ...

ESMO 2023

Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)

Anika Sharma

ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...

Tagrisso leads lung cancer market with $7B sales

AstraZeneca’s Tagrisso dominates lung cancer market with projected $7B sales by 2025

Anika Sharma

The lung cancer drug market has been notably dominated by antibodies and immunotherapies, but a recent report from GlobalData suggests ...

Pfizer wins FDA approval for lung cancer combo

Pfizer gets FDA nod for Lorbrena-Vizimpro combo to treat advanced lung cancer

Anika Sharma

Pfizer is making strategic moves to reinforce its presence in the oncology arena, with the FDA granting approval for its ...

Amgen’s Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now

Amgen’s Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now

Anika Sharma

Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...

FDA Identifies 'Systemic Bias' in Amgen's Late-Stage Lumakras Trial Ahead of Adcomm

FDA Identifies ‘Systemic Bias’ in Amgen’s Late-Stage Lumakras Trial Ahead of Adcomm

Anika Sharma

As an FDA advisory committee prepares to deliberate on the data supporting Amgen’s groundbreaking drug Lumakras, a pre-meeting briefing document ...

TROPION-Lung04, datopotamab deruxtecan, Dato-DXd, Imfinzi, NSCLC, International Association for the Study of Lung Cancer, IASLC 2023, Immunotherapy, antibody-drug conjugate

Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial

Anika Sharma

The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...

Tecentriq, Roche, Lung Cancer, NSCLC, Alecensa, Clinical trial results, ALK-positive NSCLC

Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead

Anika Sharma

With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...

Roche, Lung Cancer, TIGIT, Tecentriq, tiragolumab, Clinical trial results, NSCLC

Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks

Anika Sharma

An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...

Lumakras, Amgen, KRAS mutation, KRAS inhibitor, KRAS G12C mutation, NSCLC, Krazati

FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties

Anika Sharma

Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...

KRASG12C Inhibitors for NSCLC: How Garsorasib Stands Out

Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC

SG Tylor

Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced non–small cell lung cancer ...

Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC

Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC

SG Tylor

In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...

New Combination Therapy Shows Promise for Lung Cancer Patients with Rare Mutation

Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC

SG Tylor

Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...

FDA states that LN-145 in NSCLC is likely to receive accelerated approval

FDA states that LN-145 in NSCLC is likely to receive accelerated approval

SG Tylor

Source – Iovance Biotherapeutics The Phase II IOV-LUN-202 trial of LN-145 in patients with post-anti-PD-1 non-small cell lung cancer (NSCLC) ...

The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising

The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising

SG Tylor

Source – MAIA Biotechnology Two patients with advanced non-small cell lung cancer (NSCLC) have not experienced disease progression for 12.2 ...

Datopotamab Deruxtecan Meets Dual Primary Endpoint in TROPION-Lung01 Phase III Trial for Advanced Non-Small Cell Lung Cancer - Pharmtales

DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

SG Tylor

On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...

Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression - Pharmtales

Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression

SG Tylor

First-line treatment with pembrolizumab (Keytruda) has demonstrated long-term survival benefits and durable responses in patients with PD-L1-positive, locally advanced or ...